Aldeyra Therapeutics
ALDX
102 hedge funds and large institutions have $116M invested in Aldeyra Therapeutics in 2024 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 32 increasing their positions, 33 reducing their positions, and 17 closing their positions.
289% more call options, than puts
Call options by funds: $871K | Put options by funds: $224K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.28% less ownership
Funds ownership: 60.43% → 60.15% (-0.28%)
3% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 33
3% less funds holding
Funds holding: 105 → 102 (-3)
7% less capital invested
Capital invested by funds: $125M → $116M (-$9.24M)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
Top Buyers
Top Sellers
ALDX Hedge Fund Activity: Q1 2024 in Review
102 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2024, worth a combined $116M — down 7.4% from $125M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ALDX and 14 opened new positions — a net loss of 3 holders — while 33 trimmed existing stakes and 32 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.41M. The largest seller was Morgan Stanley, cutting an estimated $1.61M.
- 102 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2024, down from 105 in Q4 2023.
- Funds reported $116M of Aldeyra Therapeutics stock for Q1 2024, down 7.4% quarter-over-quarter.
- 14 funds opened new Aldeyra Therapeutics positions in Q1 2024 and 17 closed out, a net change of -3 holders.
- The largest Aldeyra Therapeutics buyer in Q1 2024 was Renaissance Technologies, an estimated $1.41M added.
- The largest Aldeyra Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $1.61M sold.
Based on aggregated 13F filings for Q1 2024.